Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients

Launched by RENJI HOSPITAL · Feb 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how infections with a bacteria called Clostridioides difficile (often referred to as C. diff) affect the gut bacteria and substances produced in the intestines of patients with inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease. Researchers want to find out which specific types of bacteria and metabolites (small molecules produced by gut bacteria) can help identify IBD patients who are infected or at higher risk of being infected with C. diff.

To participate in this study, individuals must be between 18 and 75 years old and currently diagnosed with ulcerative colitis or Crohn's disease while experiencing diarrhea. Those with other infections or certain metabolic or inflammatory diseases will not be included. Participants will need to provide samples after 4-6 weeks of therapy. The study is currently recruiting participants, and it aims to better understand the relationship between gut health and C. diff infections in IBD patients, which may lead to improved treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • inpatients diagnosed with ulcerative colitis or Crohn's disease in Renji hospital
• • age from 18 to 75 years old
• Exclusion Criteria:
• • other infection caused diarrhea
• • other metabolic diseases or inflammatory diseases
• • patients who are not able to send back samples 4-6 weeks after therapy